Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
481-500 of 3,900 trials

Prostate Cancer: VIR-5500 Treatment

We are studying the safety and early effects of VIR-5500 in men with prostate cancer. This trial aims to understand how well the treatment works and how it is processed in the body.

Hormone-Refractory Prostate Cancer>2 yearsSafety phase (I)Oncology

Alpha-1 Antitrypsin Deficiency: Fazirsiran Treatment Study

We are investigating the long-term safety of fazirsiran for people with liver disease related to Alpha-1 Antitrypsin Deficiency. The study will also look at how this treatment affects liver health over time.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyPulmonology

Preventing Postoperative Pain in Children: Locoregional Analgesia Study

We are studying whether locoregional analgesia can help reduce long-term pain after orthopedic surgery in children. The trial compares pain levels and recovery outcomes between different pain management methods.

Postoperative Pain>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngology

Metastatic Non-Small Cell Lung Cancer: Pembrolizumab with Sacituzumab Govitecan

We are studying whether combining pembrolizumab with sacituzumab govitecan improves survival and quality of life for patients with metastatic non-small cell lung cancer. This trial compares the combination treatment to pembrolizumab alone.

Metastatic Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Hereditary Angioedema: OCTA-C1-INH Treatment Study

We are studying a new intravenous treatment for people with hereditary angioedema to see if it effectively relieves symptoms during acute attacks. The trial includes adolescents and adults, and also looks at safety and quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients

We are studying whether Pembrolizumab can help reduce the JCV viral load in the cerebrospinal fluid of immunocompromised patients with PML. This trial aims to understand its effects on neurological health and overall survival.

Progressive Multifocal Leukoencephalopathy (PML)6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology

Lung Cancer: Adagrasib Dosing Study

We are comparing two dosing schedules of adagrasib for patients with non-small cell lung cancer and a KRAS G12C mutation who have had previous treatments. The goal is to find out which regimen works better and is safer.

Non-small cell lung cancerEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Melatonin for Chronic Back Pain

We are studying whether melatonin can help reduce pain and improve sleep in people with chronic back pain. This trial compares melatonin to a placebo to see which is more effective.

Chronic Back Pain≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Rare Ovarian Cancer: Abemaciclib and Letrozole Study

We are investigating the effects of a new treatment combining abemaciclib and letrozole for women with estrogen receptor positive rare ovarian cancer. The study aims to understand how well this treatment works and its impact on quality of life.

Adult-type Granulosa Cell TumorLow-Grade Serous Ovarian Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

MK-2870 vs Chemotherapy for Advanced Lung Cancer

We are studying a new treatment, MK-2870, for patients with advanced nonsquamous non-small cell lung cancer who have specific genetic mutations. The goal is to see if it works better than standard chemotherapy options.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Investigational MedicinesOncology

Advanced Non-Small Cell Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have a specific genetic mutation. This trial compares the effects of the combination treatment to chemotherapy alone.

Non-Small Cell Lung Cancer6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Staphylococcus aureus Bacteremia: SNAP Trial

We are testing various treatment options for patients with Staphylococcus aureus bacteremia to see how they impact survival and other health outcomes. This study aims to improve care for those affected by this serious infection.

Staphylococcus aureus Bacteremia3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

B-Cell Malignancies: Oral ABBV-101 Study

We are evaluating a new oral medication for adults with B-cell malignancies to see how it affects disease activity and its safety. This study will help us understand how the medication works in the body.

Non-Hodgkin's B-Cell Lymphoma>2 yearsSafety phase (I)HematologyOncology

Cardiogenic Shock: Early Empagliflozin Treatment

We are studying if starting empagliflozin early helps patients with cardiogenic shock improve their heart function and reduce hospital visits. This trial compares the new treatment with standard care to see which is more effective.

Cardiogenic Shock3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Triple-Negative Breast Cancer: New Treatment Strategies

We are exploring new therapies for patients with early relapsed metastatic triple-negative breast cancer. The study aims to understand their safety and effectiveness compared to existing options.

Hormone-Receptor Negative and HER2-Negative Breast CancerSafety phase (I)Efficacy phase (II)Oncology

Liver Surgery: Octreotide Study

We are investigating whether octreotide can reduce blood loss and improve stability during laparoscopic liver surgery. This study will help us understand its effects compared to a placebo.

Laparoscopic Hepatectomy Surgery>2 yearsEfficacy phase (II)Standard MedicinesHepatologyInternal MedicineOtolaryngology

Pulmonary Arterial Hypertension: Seralutinib Inhalation Study

We are studying whether inhaling seralutinib helps improve exercise capacity in people with pulmonary arterial hypertension. The trial also looks at safety and other health benefits compared to a placebo.

Pulmonary Arterial Hypertension1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyPulmonology

Acute Brain Injury: Apomorphine and Psilocybin Study

We are exploring the safety of two medications in patients who are unresponsive in the ICU due to brain injury. The goal is to find effective doses while monitoring for any side effects.

Coma and Disorders of Consciousness3-6 monthsSafety phase (I)Investigational MedicinesNeurologyPsychiatry

Metastatic Breast Cancer: Treatment Combinations Study

We are evaluating the effectiveness and safety of various treatment combinations for patients with metastatic breast cancer. This study aims to find better options for managing the disease.

Metastatic Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Atopic Dermatitis in Children: Tralokinumab Treatment

We are studying whether a new treatment with tralokinumab and topical steroids helps children aged 2 to under 12 and infants aged 6 months to under 2 manage moderate-to-severe atopic dermatitis better than a placebo. The trial also looks at how this treatment affects daily life and skin health.

Atopic Dermatitis1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology